Serum Concentrations of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Risk of Adverse Events in Pediatric Patients With Cancer and Fever in Neutropenia | Zendy

Roland A. Ammann | Zendy; Nicole Bodmer | Zendy; Arne Simon | Zendy; Philipp Agyeman | Zendy; Kurt Leibundgut | Zendy; Luregn J. Schlapbach | Zendy; Felix Niggli | Zendy

Open Access

Serum Concentrations of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Risk of Adverse Events in Pediatric Patients With Cancer and Fever in Neutropenia

Author(s) -

Roland A. Ammann,

Nicole Bodmer,

Arne Simon,

Philipp Agyeman,

Kurt Leibundgut,

Luregn J. Schlapbach,

Felix Niggli

Publication year - 2013

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/pit005

Subject(s) - medicine , mannan binding lectin , neutropenia , febrile neutropenia , adverse effect , serine protease , immunology , lectin , lectin pathway , protease , complement system , antibody , enzyme , biology , toxicity , classical complement pathway , biochemistry

It is unknown whether serum concentrations of mannan-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) influence the risk of adverse events (AEs) in children with cancer presenting with fever in neutropenia (FN).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research